Postoperative Effects of Cinobufacini Capsules on Pain Reduction, Mitigation of Oxidative Stress, Immune Modulation, and Inflammatory Response in Differentiated Thyroid Cancer.
{"title":"Postoperative Effects of Cinobufacini Capsules on Pain Reduction, Mitigation of Oxidative Stress, Immune Modulation, and Inflammatory Response in Differentiated Thyroid Cancer.","authors":"Hui Zhao, Han Yu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the impact of cinobufacini capsules in patients who underwent total thyroidectomy for differentiated thyroid cancer (DTC).</p><p><strong>Methods: </strong>A prospective cohort study was conducted, and a total of 120 DTC patients were selected. The patients were divided into two groups: a control group receiving standard postoperative treatment (n = 60) and a cinobufacini group receiving cinobufacini capsules in addition to standard treatment (n = 60). Various assessments were conducted, including pain evaluation, lymphocyte subset measurement, as well as the quantification of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), free sulfhydryl (-SH) levels, and lipid hydroperoxides (LOOH) in serum.</p><p><strong>Results: </strong>Both groups experienced reduced pain levels after one month of treatment, with the cinobufacini group demonstrating a more significant reduction. In comparison to the control group, one month of cinobufacini treatment resulted in substantial increases in NK cell activity, percentages of NK cells, activated NK cells, and CD8+ T-cells. It also led to the mitigation of oxidative stress and inflammation response.</p><p><strong>Conclusions: </strong>These findings indicate that cinobufacini may serve as an adjunctive therapy for DTC patients, offering benefits in pain management, immune modulation, and reducing inflammation and oxidative stress after surgery.</p>","PeriodicalId":7571,"journal":{"name":"Alternative therapies in health and medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alternative therapies in health and medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to evaluate the impact of cinobufacini capsules in patients who underwent total thyroidectomy for differentiated thyroid cancer (DTC).
Methods: A prospective cohort study was conducted, and a total of 120 DTC patients were selected. The patients were divided into two groups: a control group receiving standard postoperative treatment (n = 60) and a cinobufacini group receiving cinobufacini capsules in addition to standard treatment (n = 60). Various assessments were conducted, including pain evaluation, lymphocyte subset measurement, as well as the quantification of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), free sulfhydryl (-SH) levels, and lipid hydroperoxides (LOOH) in serum.
Results: Both groups experienced reduced pain levels after one month of treatment, with the cinobufacini group demonstrating a more significant reduction. In comparison to the control group, one month of cinobufacini treatment resulted in substantial increases in NK cell activity, percentages of NK cells, activated NK cells, and CD8+ T-cells. It also led to the mitigation of oxidative stress and inflammation response.
Conclusions: These findings indicate that cinobufacini may serve as an adjunctive therapy for DTC patients, offering benefits in pain management, immune modulation, and reducing inflammation and oxidative stress after surgery.
期刊介绍:
Launched in 1995, Alternative Therapies in Health and Medicine has a mission to promote the art and science of integrative medicine and a responsibility to improve public health. We strive to maintain the highest standards of ethical medical journalism independent of special interests that is timely, accurate, and a pleasure to read. We publish original, peer-reviewed scientific articles that provide health care providers with continuing education to promote health, prevent illness, and treat disease. Alternative Therapies in Health and Medicine was the first journal in this field to be indexed in the National Library of Medicine. In 2006, 2007, and 2008, ATHM had the highest impact factor ranking of any independently published peer-reviewed CAM journal in the United States—meaning that its research articles were cited more frequently than any other journal’s in the field.
Alternative Therapies in Health and Medicine does not endorse any particular system or method but promotes the evaluation and appropriate use of all effective therapeutic approaches. Each issue contains a variety of disciplined inquiry methods, from case reports to original scientific research to systematic reviews. The editors encourage the integration of evidence-based emerging therapies with conventional medical practices by licensed health care providers in a way that promotes a comprehensive approach to health care that is focused on wellness, prevention, and healing. Alternative Therapies in Health and Medicine hopes to inform all licensed health care practitioners about developments in fields other than their own and to foster an ongoing debate about the scientific, clinical, historical, legal, political, and cultural issues that affect all of health care.